Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing RNA interference (RNAi) therapeutics to treat genetic, cardio-metabolic, liver, and neurological diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company pioneers the use of RNA interference technology to silence specific genes associated with various illnesses, aiming to address unmet medical needs.
Company News
BlackRock Health Sciences Term Trust (BMEZ) recently cut its dividend, but still offers a 9.2% monthly yield. The fund focuses on healthcare innovators that could benefit from potential policy changes, with top holdings in biotech and medical technology companies.
Scenic Biotech appointed Dr. Roland W. Bürli as Chief Scientific Officer to lead development of modifier therapies for neurodegenerative and metabolic diseases, leveraging the company's Cell-Seq platform.
Vir Biotechnology reported a Q2 2025 net loss of $0.80 per share, with revenues of $1.2 million. The company advanced its clinical pipeline in hepatitis delta and oncology, maintaining $892.1 million in cash reserves while continuing to invest in research and development.
Alnylam Pharmaceuticals reported strong Q2 earnings, beating analyst expectations with $773.69 million in revenue and raising fiscal 2025 sales guidance. The company's drug Amvuttra for ATTR-CM has reached 1,400 patients, adding approximately $150 million in revenue.
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeutics.